(Q37236447)

19 August 2017

1 reference

title

From oncogene to network addiction: the new frontier of cancer genomics and therapeutics (English)

1 reference

19 August 2017

1 reference

Giovanni Tonon

1

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 August 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

4

1 reference

19 August 2017

issue

4

1 reference

19 August 2017

page(s)

569-577

1 reference

A census of human cancer genes

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Growth and antigenic properties of a biopsy-derived Burkitt's lymphoma in thymus-less (nude) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Analysis of malignancy in human cells: malignant and transformed phenotypes are under separate genetic control

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Biological assays for cellular transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Biological assays for Ras transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Integrating genetic approaches into the discovery of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Hsp90 as a capacitor for morphological evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Heat shock protein 90 as a molecular target for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Non-oncogene addiction and the stress phenotype of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Cancer proliferation gene discovery through functional genomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Mutational analysis of the tyrosine kinome in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

The consensus coding sequences of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Mutational analysis of the tyrosine phosphatome in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Patterns of somatic mutation in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

The genomic landscapes of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Characterizing the cancer genome in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

High-resolution genomic profiles of human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Can't kick that oncogene habit

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Integrative genomic approaches identify IKBKE as a breast cancer oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

A genetic screen for candidate tumor suppressors identifies REST

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Cancer genes and the pathways they control

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Signaling networks assembled by oncogenic EGFR and c-Met

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Computational systems biology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

21 January 2018

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Genetics and biology of pancreatic ductal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Common effector processing mediates cell-specific responses to stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Intrinsic tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Lethality and centrality in protein networks

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Dangerous habits of a security guard: the two faces of p53 as a drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

RAF/RAS oncogenes and mismatch-repair status

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

High-throughput oncogene mutation profiling in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.4.569

21 January 2018

Identifiers

DOI

10.2217/14796694.4.4.569

1 reference

release_p4acxfipynb77jvramft4lvbua

19 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/p4acxfipynb77jvramft4lvbua

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference